The lung adenocarcinoma PDX model with EGFR exon 19 deletion and EGFR T790M mutation was resistant to gefitinib/erlotinib, but responded to cetuximab (Martin et al., 2016). This evidence concerns the gene EGFR and lung adenocarcinoma.